Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration
Authors:
- 13 October 2025
- journal article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (1) , 81-89
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular DegenerationOphthalmology Retina, 2025
- Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2024
- Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2022
- Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2021
- Polypoidal Choroidal VasculopathyOphthalmology, 2021
- Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2020
- Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular DegenerationOphthalmology, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012